Intoxication with botulinum neurotoxin (BoNT) 1 in vivo leads to flaccid paralysis by blockade of acetylcholine release at the neuromuscular junction (1-3). The proteolytic activity of the toxin responsible for causing paralysis resides within the 50-kDa light chain domain (4, 5) and is directed against three synaptic proteins: synaptosomal-associated protein of 25-kDa (SNAP-25), vesicle-associated membrane protein (VAMP), or syntaxin (6 -11). BoNT/A and -E both cleave SNAP-25 but at distinct sites (12). Interestingly, paralysis from BoNT/A lasts for many months whereas blockade caused by BoNT/E lasts for relatively brief periods (13, 14) . Two hypotheses were proposed to account for this difference: (a) BoNT/A remains catalytically active for a longer interval than BoNT/E or, alternatively (b) the catalytic activity of both toxins is very short-term but the major SNAP-25 fragment generated by BoNT/A (P197) persists in nerve terminals and interferes with neurotransmitter release (15). The first hypothesis has been substantiated by direct demonstration of BoNT/A persistence in primary mouse spinal cord cultures, electroporated chromaffin cells, and mammalian neuromuscular junction preparations in vivo (16 -18). Evidence for the second hypothesis is indirect. Overexpressed P197 in an insulinoma Hit-T15 cell line inhibits insulin secretion (19). BoNT/A action at the neuromuscular junction produces a strong immunogenic signal for P197 within nerve terminals, indicating that P197 resides for some time in the proper intracellular regions where it could exert an inhibitory effect on neurotransmission (20, 21). However, there has been no quantitative analysis to determine whether the concentrations of P197 generated by toxin activity are able to inhibit neurotransmitter release.
Intoxication with botulinum neurotoxin (BoNT) 1 in vivo leads to flaccid paralysis by blockade of acetylcholine release at the neuromuscular junction (1) (2) (3) . The proteolytic activity of the toxin responsible for causing paralysis resides within the 50-kDa light chain domain (4, 5) and is directed against three synaptic proteins: synaptosomal-associated protein of 25-kDa (SNAP-25), vesicle-associated membrane protein (VAMP), or syntaxin (6 -11) . BoNT/A and -E both cleave SNAP-25 but at distinct sites (12) . Interestingly, paralysis from BoNT/A lasts for many months whereas blockade caused by BoNT/E lasts for relatively brief periods (13, 14) . Two hypotheses were proposed to account for this difference: (a) BoNT/A remains catalytically active for a longer interval than BoNT/E or, alternatively (b) the catalytic activity of both toxins is very short-term but the major SNAP-25 fragment generated by BoNT/A (P197) persists in nerve terminals and interferes with neurotransmitter release (15) . The first hypothesis has been substantiated by direct demonstration of BoNT/A persistence in primary mouse spinal cord cultures, electroporated chromaffin cells, and mammalian neuromuscular junction preparations in vivo (16 -18) . Evidence for the second hypothesis is indirect. Overexpressed P197 in an insulinoma Hit-T15 cell line inhibits insulin secretion (19) . BoNT/A action at the neuromuscular junction produces a strong immunogenic signal for P197 within nerve terminals, indicating that P197 resides for some time in the proper intracellular regions where it could exert an inhibitory effect on neurotransmission (20, 21) . However, there has been no quantitative analysis to determine whether the concentrations of P197 generated by toxin activity are able to inhibit neurotransmitter release.
BoNT/A and -E are unique among the BoNTs in that, under certain experimental conditions, elevated Ca 2ϩ can partially relieve a toxin-induced blockade (22) (23) (24) . The effect of Ca 2ϩ on reversing BoNT/A-induced paralysis has been reported for muscle preparations (25, 26) , hippocampal brain slices (27, 28) , synaptosomes (29) , and chromaffin cells (31) . The molecular relationship between SNAP-25 and Ca 2ϩ is not well understood, however. The altered Ca 2ϩ sensitivity observed in PC12 cells for either BoNT/A or -E (30) is consistent with earlier observations using neuromuscular or chromaffin cell preparations prior to the discovery of SNAP-25 as the toxin substrate (32) (33) (34) . Furthermore, electrophysiological results indicate that the C terminus of SNAP-25, which is directly affected by BoNT/A and -E, contributes to the initiation of two distinct Ca 2ϩ -sensitive steps in the neurotransmitter release process (31) .
SNAP-25 and P197 each bind to VAMP and syntaxin although the P197-containing complex is less stable to detergent solubilization than a complex containing SNAP-25 (35) (36) (37) . Examining the possible inhibitory role of P197 within the framework of the SNARE hypothesis (38, 39) suggests that BoNT/A damage compromises the ability of the complex to facilitate vesicle fusion. Calcium induces a conformational transition of the trimeric SNARE complex from a cis (nonsecretory) to a trans orientation which triggers vesicle fusion and neurotransmitter release (40, 41) . Given these two effects, SNAP-25 cleavage and reduced Ca 2ϩ sensitivity, it is possible that BoNT/A action on SNAP-25 alters other interactions which affect neurotransmitter release. To this end, it was demonstrated that Ca 2ϩ stimulates binding between SNAP-25 and P197 with synaptotagmin (30) . Hence, there may be multiple roles for SNAP-25 and Ca 2ϩ in the release process (34, (41) (42) (43) . Calcium ionophores have been used successfully to discriminate between the effects of voltage-gated Ca 2ϩ channels and direct effects of elevated intracellular Ca 2ϩ on BoNT/A action (27, 28, 44, 45) . This approach has been extended to the present study to investigate the requirement for intracellular Ca 2ϩ in overcoming the inhibitory action of BoNT/A in mouse spinal cord cultures. The findings demonstrate that a mathematical correlation exists between the generation of P197 by BoNT/A and inhibition of Ca 2ϩ -dependent neurotransmitter release, indicating that the amount of P197 attained within neurons will block exocytosis. (46, 47) . Briefly, spinal cords were removed from fetal mice at gestation day 13, dissociated with trypsin, and plated on Vitrogen TM 100-coated dishes (Collagen Corp., Palo Alto, CA) at a density of 10 6 cells/dish. Cultures were maintained for 3 weeks at 37°C in an atmosphere of 90% air, 10% CO 2 before addition of toxins. Growth medium consisted of minimum essential medium (formula 82-0234AJ; Life Technologies, Inc., Bethesda, MD) supplemented with 5% heat-inactivated horse serum and a mixture of complex factors (48) . Cultures were incubated with BoNT diluted with growth medium for times indicated in figure legends. BoNT-containing medium was removed by aspiration; cells were rinsed with toxin-free medium and prepared for Western blot analysis or neurotransmitter release.
EXPERIMENTAL PROCEDURES

Materials-Monoclonal
Protein and Western Blot Analysis-Protein was prepared by dissolving cells in 1% SDS with 1 mM EDTA and 1 mM EGTA. The slurry was transferred to 1.5-ml microcentrifuge tubes, incubated in a 95°C water bath for 5 min to inactivate proteases, and then stored at Ϫ20°C. Immediately prior to use samples were thawed, mixed with equal volumes of Tris-Tricine sample buffer (Bio-Rad), heated at 95°C for 4 min, and then separated by SDS-polyacrylamide gel electrophoresis. Equal quantities of protein were loaded onto 16.5% acrylamide gels prepared by the method of Laemmli (49) . Proteins were separated using 0.1 M Tris-Tricine, pH 8.3 (50) , and then transferred to polyvinylidene difluoride membrane with a buffer containing 192 mM glycine, 25 mM Tris, pH 8.3, and 12% methanol. Membrane development was performed as previously described (16) .
Neurotransmitter Release and Quantitation-Potassium-stimulated Ca 2ϩ -dependent neurotransmitter release was determined as previously described (51) . Cultures were labeled with [ 3 H]glycine for 0.5 h at 35°C and then washed with a series of low K ϩ -containing buffers. Unless otherwise indicated, glycine release was stimulated by addition of 56 mM K ϩ and 2 mM Ca 2ϩ to cultures; stimulation medium was collected after 5 min at 35°C. Calcium-dependent release was determined by subtracting baseline radioactivity secreted from cultures in the absence of Ca 2ϩ , and expressed as a percentage of the total cellular radioactivity.
Regression Analysis and Curve Fitting-Scanned images of Western blots were produced and edited utilizing NIH Image (National Institutes of Health, Bethesda, MD). Where indicated, images were digitally analyzed using IPLab Gel software (Scanalytics, Inc., Fairfax, VA). Nonlinear regression analysis of data was performed with Sigma Plot (SPSS Science, Inc., Chicago, IL). Error bars represent standard deviations of triplicate determinations unless otherwise indicated.
RESULTS
Concentration-dependent Effects of BoNT/E on SNAP-25
Cleavage and Neurotransmitter Release-BoNT/E treatment of spinal cord cell cultures results in cleavage of SNAP-25 in a concentration-dependent manner (Fig. 1A) . Under the conditions of these experiments, the IC 50 for BoNT/E cleavage of SNAP-25 is ϳ50 pM. Measurement of synaptic function indicates that K ϩ -evoked glycine release is inhibited to the same extent as SNAP-25 cleavage (Fig. 1B) . In control cultures, the extent of glycine release is related to Ca BoNT/E block of glycine release which varies from 49 to 55 pM for the conditions tested (Fig. 1B) .
The model in Fig. 1C illustrates the effect of BoNT/E on the release process. In this model, SNAP-25 is shown to interact with elements (X) required for neurotransmitter release with an affinity represented by K d . Potassium depolarization stimulates release in a Ca 2ϩ -dependent manner. Release is directly proportional to the amount of SNAP-25 present. As SNAP-25 is cleaved by increasing concentrations of BoNT/E, neurotransmitter release decreases to a similar extent. BoNT/E-cleaved SNAP-25 (P180) has been shown to interact with VAMP and syntaxin in vitro (36, 37) . However, our data indicate that in this intact neuronal system, P180 does not interfere with K ϩ -evoked release, possibly because P180 interacts with X very weakly relative to SNAP-25. Furthermore, increasing extracellular Ca 2ϩ above physiological concentrations does not overcome the block (Fig. 3) , similar to findings with neuromuscular preparations (14) .
Concentration-dependent Effects of BoNT/A on SNAP-25 Cleavage and Neurotransmitter Release-Unlike
BoNT/E, dose-response data with BoNT/A produce nonoverlapping curves for SNAP-25 proteolysis and blockade of neurotransmitter release (Fig. 2B) . SNAP-25 cleavage occurs with an approximate IC 50 of 3 pM and glycine release is inhibited with IC 50 values decreasing from 0.3 to 0.1 pM as Ca 2ϩ concentrations decrease from 2 to 0.15 mM in the release medium (Fig. 2B) . Increasing Ca 2ϩ to 8 or 10 mM yielded results identical to that obtained with 2 mM Ca 2ϩ (data not shown). At Ca 2ϩ concentrations lower than 2 mM, a greater degree of inhibition occurs relative to SNAP-25 cleavage (Fig. 2B) . At all Ca 2ϩ concentrations tested, the slopes for neurotransmitter release were the same. Comparing these slopes with the slope for SNAP-25 yields a ratio of ϳ2:1. Fig. 2C depicts possible interactions between SNAP-25 and P197 and their combined effects on the release process. In this model P197 binds to elements X much the same as SNAP-25. Because elevated Ca 2ϩ has been shown previously to reverse BoNT/A inhibition in brain slices (27) , PC12 cells (29) , and neuromuscular preparations (52), we hypothesize that neurotransmitter release through the P197-X pathway would require Ca 2ϩ in excess of that achieved during normal neuronal stimulation. Elevated Ca 2ϩ above normal levels is depicted with the term Ca 2ϩ Ј. This model allows us to predict the relationship between SNAP-25 cleavage and block of transmitter release. Assuming (a) that P197 interacts with elements X with the same or nearly the same affinity as SNAP-25, and (b) that at any given dose of BoNT/A, the molar sum of the remaining SNAP-25 and P197 will equal the amount of SNAP-25 in the absence of toxin, the profile in Fig. 2D is generated. According to this model, the ratio of the slope for neurotransmitter release relative to SNAP-25 is exactly 2:1. The data for neurotransmitter release measured with 2 mM Ca 2ϩ (Fig. 2B) overlap the predicted result.
Extracellular Ca 2ϩ Effects on Overcoming BoNT Intoxication-Because at lower Ca 2ϩ concentrations, BoNT/A-exposed cultures show a greater block in transmitter release (Fig. 2) (Fig. 3) . Glycine release from BoNT/A-treated cultures is similarly Ca 2ϩ dependent with an EC 50 value of 1.0 Ϯ 0.1 mM and a plateau value that is 23% of control release (Fig. 3) . Maximum release for both control and BoNT/A-treated cul- tures is attained when Ca 2ϩ exceeds 2 mM (Fig. 3 ) and the slope of release is unaffected by toxin with an estimated Hill coefficient of 2.2 Ϯ 0.3 (53, 54) . Glycine release from BoNT/E-treated cultures is not detected at any concentration of Ca 2ϩ tested (Fig. 3) . This indicates that the rise of intracellular Ca 2ϩ resulting from Ca 2ϩ -channel activation can restore some function to BoNT/A-but not to BoNT/E-treated neurons, consistent with results from Figs. 1 and 2 .
Intracellular Ca 2ϩ Effects on Overcoming BoNT/A Intoxication-To examine the effects of increased intracellular Ca 2ϩ above levels attained from Ca 2ϩ -channel activation, glycine release was evoked by 56 mM K ϩ in the presence and absence of 2 mM Ca 2ϩ and 5 M ionomycin, a Ca 2ϩ -specific ionophore. Ionomycin partially restores glycine release after exposure to BoNT/A (Fig. 4) . Treatment with BoNT/A reduces glycine release to ϳ23% of control release. Addition of ionomycin in combination with Ca 2ϩ reduces the effect of BoNT/A, raising glycine release to 60% of control values. To determine the source of Ca 2ϩ that contributes to this reversal, glycine release was assayed with ionomycin either in the absence of extracellular Ca 2ϩ , or after having treated cultures with thapsigargin to deplete intracellular Ca 2ϩ stores (55, 56) . The absence of any release with zero external Ca 2ϩ with ionomycin and the failure of thapsigargin to affect the ionomycin-dependent release provide evidence that internal Ca 2ϩ stores do not contribute significantly to ionomycin's reversal of the BoNT/A-induced block.
To expand upon this finding, cultures were treated with 1 nM BoNT/A or BoNT/E for 24 h and neurotransmitter release was measured in the presence of 10 M ionomycin in 56 mM K ϩ with various external Ca 2ϩ concentrations. Ionomycin produces a significant reversal of the BoNT/A block at all Ca 2ϩ concentrations tested with complete recovery occurring near 2 mM Ca 2ϩ . Unlike K ϩ /Ca 2ϩ stimulation alone, stimulation in the presence of ionomycin partially alleviates BoNT/E-induced block with maximum glycine release at 53% of control cultures (Fig. 5 ).
Within these experimental conditions, BoNT/A-and/E-treated neurons are about 4-and 7-fold less sensitive to Ca 2ϩ , respectively, than untreated neurons. Ionomycin has two measurable effects on reversing BoNT/E action: neurons release more gly- cine and demonstrate higher sensitivity to Ca 2ϩ . In the case of BoNT/A, ionomycin stimulates release of glycine to control values. However, ionomycin does not alter the EC 50 value for Ca 2ϩ which is 0.8 Ϯ 0.1 mM (Fig. 5 ) compared with 1.0 Ϯ 0.1 mM obtained for the partial release achieved in the absence of ionomycin (Fig. 3 ). Ionomycin at the tested concentration does not affect cultures that were not treated with toxin; neither the Ca 2ϩ sensitivity nor the extent of glycine release was altered (Fig. 5) .
DISCUSSION
In this study, we examined the relationship between blockade of neurotransmitter release and cleavage of SNAP-25 caused by BoNT/A and -E to aid in understanding how BoNT/A seems to derive greater potency than BoNT/E (14, 22, 26, 32) . Both BoNTs induce a concentration-dependent block in synaptic vesicle exocytosis and proteolysis of SNAP-25. However, it appears likely that in addition to disabling SNAP-25, BoNT/A action has a secondary inhibitory effect. The nonoverlapping pattern of SNAP-25 cleavage and block of K ϩ -evoked transmitter release in this latter case points to the formation of an inhibitory complex containing a cleavage fragment produced by BoNT/A. Most simply, BoNT/A action on SNAP-25 produces a dual effect: a reduction in functional SNAP-25 and production of a fragment that antagonizes synaptic vesicle fusion.
The identity of this fragment could be either the 197-amino acid fragment, P197, or the smaller 9-residue fragment cleaved from the C terminus. C-terminal peptides of SNAP-25 disrupt synaptic vesicle trafficking in permeabilized chromaffin cells (57, 58) . Peptides with sequences corresponding to the C-terminal 26 and 20 amino acids inhibited neurosecretion with IC 50 values of ϳ0.25 and 20 M, respectively (58, 59) . A 12-residue peptide of the C terminus failed to inhibit release to any significant extent (60) . The correlation of shorter peptide length with lower potency suggests that the 9-residue cleavage fragment generated by BoNT/A does not interfere with neurotransmitter release.
An inhibitory role of P197 was demonstrated by transfection of P197 into an Hit-T15 cell line and subsequent inhibition of insulin secretion (19) . Additionally, P197 has been shown to interact directly with the SNARE proteins VAMP and syntaxin in a manner similar to SNAP-25 (35, 37) . Based on the estimated half-life for BoNT/A being 3 days (61), detection of P197 in intoxicated motor nerve terminals in vivo generated the hypothesis that P197 was degraded slowly relative to SNAP-25 and could, therefore, interfere with the normal vesicular pathway for neurotransmitter release for weeks or months (20, 21) . Two studies since then have provided direct evidence that BoNT/A catalytic activity persists within neurons with a halflife far greater than 3 days (16, 18) . Information on the degradation rate of P197, although indirect at present, suggests that it occurs at a rate similar to SNAP-25 (16) . The prolonged duration of the catalytic action of BoNT/A does not, however, invalidate the role of SNAP-25 cleavage products in the extent of paralysis. For example, the persistence of BoNT/A activity would provide a constant production of P197 to account for its continued presence in intoxicated nerve terminals (20, 21) . Furthermore, because nerve stimulation accelerates the onset of paralysis (23, 62, 63) , toxin probably accumulates within nerve terminals where production of P197 would occur in the proximity of vesicular activity. Additive effects on muscle twitch from the production of P197 and loss of SNAP-25 could also explain why muscle paralysis occurs prior to detectable loss of SNAP-25 by immunohistochemical methods (64) .
The model presented in Fig. 2C predicts that cleavage of x% of the SNAP-25 population would result in a 2x% block of neurotransmitter release. This is based on simple competition of P197 and SNAP-25 for components of the fusion complex and the relationship is depicted graphically in Fig. 2D . Otto et al. (72) reported that cleavage of approximately half of SNAP-25 in synaptosomal preparations caused nearly a complete block of Ca 2ϩ -dependent glutamate secretion, in agreement with our model and experimental observations. In contrast to the sigmoidal curve observed for BoNT/E (Fig. 1B) , the linear relationship of SNAP-25 cleavage relative to BoNT/A concentration may reflect the preferential anchoring of BoNT/A (20) but not BoNT/E within nerve terminals. SNAP-25 cleavage, therefore, may represent both BoNT/A concentration and movement of SNAP-25 within proximity of the toxin, for example, SNAP-25 must be transported to the toxin. The model does not require that SNAP-25-X is necessarily composed of VAMP and syntaxin; however, the current SNARE hypothesis (38, 39) would support the involvement of these or other proteins (30, 65, 66) .
BoNT/E-treated spinal cord cultures developed a block in neurotransmitter release no greater than the extent of SNAP-25 cleavage. The direct relationship between SNAP-25 cleavage and neurotransmitter blockade indicates that, in intact neurons, SNAP-25 fragments created by BoNT/E do not interfere with the release process. Neurotransmitter release from BoNT/E-treated spinal cord neurons is approximately 7-fold less sensitive to Ca 2ϩ than release from untreated neurons when ionomycin is used, although in the absence of ionomycin release does not occur. The ionomycin/Ca 2ϩ combination could not produce a full recovery, however. Similar observations were obtained with other neuronal preparations (28, 45) and are consistent with observations in vivo that the minimal amount of the K ϩ channel blocker 3,4-diaminopyridine that stimulates a full recovery from BoNT/A does not elicit recovery from BoNT/E (14) .
Unlike BoNT/E-treated neurons, glycine release from BoNT/ A-treated neurons could be elicited without ionomycin. This release was Ca 2ϩ -dependent with an EC 50 value for external Ca 2ϩ of 1.0 mM, approximately 5-fold higher than controls (0.21 mM). At the lower concentrations of Ca 2ϩ tested, BoNT/A completely blocked K ϩ -stimulated release and at higher Ca 2ϩ concentrations, maximal release was ϳ23% of the release from control cultures. The effect of Ca 2ϩ on the release process is consistent with studies using intact chromaffin cells and hippocampal neurons (31, 53, 67, 68) ; i.e. a pool of neurotransmitter can be released after complete cleavage of SNAP-25 although the concentration of Ca 2ϩ required for this to occur is higher than physiological Ca 2ϩ levels. Release that occurs despite treatment with BoNT/A may reflect the weaker ability of P197 relative to SNAP-25 to facilitate Ca 2ϩ requiring step(s) given the extent of Ca 2ϩ influx that occurs under normal physiological conditions.
To further investigate the possible P197-release pathway (Fig. 2C) , we employed ionomycin to determine whether elevated cytosolic Ca 2ϩ would fully reverse the effects of BoNT/A (24, 29, 69) . Ionomycin improved the efficiency of vesicular release in BoNT/A-treated neurons. The apparent EC 50 for Ca 2ϩ in the presence and absence of ionomycin was statistically unaffected, 0.8 Ϯ 0.1 mM compared with 1.0 Ϯ 0.1 mM, respectively. Lack of an effect on Ca 2ϩ sensitivity and promotion of a full recovery of transmitter release suggests that ionomycin facilitates the hypothesized P197 release process by raising Ca 2ϩ above physiologically attainable levels. An alternative explanation is that the action of an undetectable population of uncleaved SNAP-25 could account for the observed synaptic release. If this were the case, however, and SNAP-25 were solely responsible, then BoNT/A treatment would reduce the plateau values for transmitter release but the observed EC 50 value for Ca 2ϩ would approximate the value for neurons not treated with toxin, i.e. 0.2 mM.
The lower Ca 2ϩ sensitivity following BoNT/A exposure may be due to disruption of several fusion processes. P197, for example, may hinder vesicle trafficking in nerve terminals. BoNT/A and tetanus neurotoxin cause significant accumulation of synaptic vesicles at active zones (63, 70) . These vesicles, unable to fuse with the presynaptic membrane, might produce a physical obstruction for the recruitment of new synaptic vesicles to dock and fuse upon Ca 2ϩ -dependent stimulation (31, 63, 71) . Hence, we show that an intact neuronal system treated with BoNT/A requires more Ca 2ϩ to attain maximal release. This effect, in part, may be due to changes in the dynamics of synaptic vesicle movement in and near release sites caused by one or more Ca 2ϩ -related changes from SNAP-25 cleavage (30) . Primary spinal cord cultures were used to provide the first proof that catalytic activity of BoNT/A but not BoNT/E ensues for many months following intoxication (16) . This finding is consistent with in vivo observations that BoNT/A but not BoNT/E causes long-term paralysis (13, 18) . In the present work, Ca 2ϩ stimulates release of neurotransmitter with a Hill coefficient of approximately 2 in the absence of toxin, which is consistent with electrophysiological estimates (54, 67) . Calcium stimulates release following exposure to BoNT/A and to a lesser extent, BoNT/E, each observation being similar to in vivo experiments with local injections of either toxin into the extensor digitorum longus muscle of rats (14, 22, 23) . Our data demonstrate that the amount of P197 generated by BoNT/A is sufficient to block neuronal activity in a concentration-dependent manner. Furthermore, the ability of P197 to inhibit release is based upon its ability to compete against uncleaved SNAP-25 in the release mechanism. In support of this latter assertion, electroporation of anti-toxin antibodies into BoNT/A-treated, chromaffin cells accelerates the recovery of secretion by nearly 10-fold (17) , indicating that inactivation of BoNT/A allows newly synthesized SNAP-25 to displace P197. This demonstrates that the effect of P197 is brief without BoNT/A activity indicating P197 itself has a brief lifetime relative to BoNT/A. Integrating these observations into a unified model we suggest that paralysis produced by BoNT/A, (a) is due to persistent catalytic activity of this toxin within nerve terminals and (b) is caused by loss of functional SNAP-25 and concomitant generation of P197 that competes with the remaining intact SNAP-25 to exacerbate the block.
